OOIR: Observatory of International Research

Papers

(The median citation count of Gastric Cancer is 3. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)

Article	Citations
Correction to: Real-world safety and effectiveness of nivolumab in Japanese patients with unresectable advanced or recurrent gastric/gastroesophageal junction cancer that has progressed after chemothe	805
Decorin as a key marker of desmoplastic cancer-associated fibroblasts mediating first-line immune checkpoint blockade resistance in metastatic gastric cancer	89
An observational study of the effectiveness and safety of nivolumab plus chemotherapy for untreated advanced or recurrent gastric cancer in Japanese real-world settings: the G-KNIGHT study	81
Predicting chemotherapy responsiveness in gastric cancer through machine learning analysis of genome, immune, and neutrophil signatures	68
Helicobacter pylori and gastric cancer: a lysosomal protease perspective	43
Risk prediction model for gastric cancer within 5 years in healthy Korean adults	42
Clinicopathological significance of microsatellite instability and immune escape mechanism in patients with gastric solid-type poorly differentiated adenocarcinoma	40
The putative pleiotropic functions of meprin β in gastric cancer	38
DNA mismatch repair deficiency and outcomes of patients with locally advanced gastric cancer treated with preoperative docetaxel, oxaliplatin, and S-1 plus surgery and postoperative S-1 or surgery plu	38
Digital histopathological images of biopsy predict response to neoadjuvant chemotherapy for locally advanced gastric cancer	37
Dose–response association between cigarette smoking and gastric cancer risk: a systematic review and meta-analysis	37
Ubiquitous mitochondrial creatine kinase promotes the progression of gastric cancer through a JNK-MAPK/JUN/HK2 axis regulated glycolysis	35
Metabolic reprogramming as a key regulator in Helicobacter pylori-infected gastric cancer	35
Novel affibody molecules targeting the AXL extracellular structural domain for molecular imaging and targeted therapy of gastric cancer	34
FERMT2 drives anoikis resistance and peritoneal metastasis by enhancing extracellular matrix deposition in gastric cancer	32
International consensus on the management of metastatic gastric cancer: step by step in the foggy landscape	30
Comment on: Statin use in relation to long-term survival after gastrectomy for gastric adenocarcinoma: a Swedish population-based cohort study	29
Type 2 diabetes in patients undergoing gastric cancer surgery: areas requiring disease-specific glycemic management	29
Minimally invasive versus open completion total gastrectomy for remnant gastric cancer: a nationwide propensity score-matched analysis	28
Prognostic significance of tertiary lymphoid structures in gastric neuroendocrine carcinoma with association to delta-like ligand 3 and neuroendocrine expressions	27
Crosstalk between cancer-associated fibroblasts and immune cells in peritoneal metastasis: inhibition in the migration of M2 macrophages and mast cells by Tranilast	27
Correction: International consensus on the management of metastatic gastric cancer: step by step in the foggy landscape	26
The combination of gene hyperamplification and PD-L1 expression as a biomarker for the clinical benefit of tislelizumab in gastric/gastroesophageal junction adenocarcinoma	26
Outcomes after gastrectomy according to the Gastrectomy Complications Consensus Group (GCCG) in the Dutch Upper GI Cancer Audit (DUCA)	25
Ramucirumab plus paclitaxel as a second-line treatment in HER2-positive gastric cancer: subgroup analysis of a nationwide, real-world study in Korea (KCSG-ST19-16)	25

LncRNA expression signature identified using genome-wide transcriptomic profiling to predict lymph node metastasis in patients with stage T1 and T2 gastric cancer	25
Addition of docetaxel to S-1 results in significantly superior 5-year survival outcomes in Stage III gastric cancer: a final report of the JACCRO GC-07 study	25
Serum TFF2 as a more reliable biomarker for gastric cancer and early gastric cancer: a cross-sectional population-based study	24
FBXW7 regulates the sensitivity of imatinib in gastrointestinal stromal tumors by targeting MCL1	23
Antibody–drug conjugates in gastric cancer: from molecular landscape to clinical strategies	23
Soluble PD-L1 as a diagnostic and prognostic biomarker in resectable gastric cancer patients	23
Volume of hepatoid component and intratumor M2 macrophages predict prognosis in patients with hepatoid adenocarcinoma of the stomach	22
The impact of contour maps on estimating the risk of gastrointestinal stromal tumor recurrence: indications for adjuvant therapy: an analysis of the Kinki GIST registry	22
Nivolumab plus chemotherapy in patients with HER2-negative, previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: 3-year follow-up of the ATTRACTION-4 ra	21
Global prevalence of claudin 18 isoform 2 in tumors of patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma	21
Circulating tumor DNA predicts clinical benefits of immune checkpoint blockade in HER2-negative patients with advanced gastric cancer	20
Optimal treatment strategy after first-line induction therapy in advanced HER2-positive oeso-gastric adenocarcinoma—a retrospective, international, multicentric AGEO study	20
Time-sequential prediction of postoperative complications after gastric cancer surgery using machine learning: a multicenter cohort study	20
Effect of single-shot intrathecal morphine versus continuous epidural analgesia on length of stay after gastrectomy for cancer: a retrospective cohort study	19
Potential therapeutic targets discovery by transcriptome analysis of an in vitro human gastric signet ring carcinoma model	19
Systematic review of health-related quality of life (HRQoL) issues associated with gastric cancer: capturing cross-cultural differences	18
Prognostic value of post-operative serum procalcitonin in gastric adenocarcinoma patients undergoing radical gastrectomy: propensity score matching analysis of extended cohort from a prospective bi-ce	18
CAF promotes chemoresistance through NRP2 in gastric cancer	18
Suppression of galectin-4 attenuates peritoneal metastasis of poorly differentiated gastric cancer cells	18
Development and application of deep learning-based diagnostics for pathologic diagnosis of gastric endoscopic submucosal dissection specimens	18
Effect of preoperative chemotherapy on the histopathological classification of gastric cancer	18
A multicenter, open-label, single-arm phase I trial of neoadjuvant nivolumab monotherapy for resectable gastric cancer	18
Janus kinase inhibitor overcomes resistance to immune checkpoint inhibitor treatment in peritoneal dissemination of gastric cancer in C57BL/6 J mice	17
Angiotensin receptor blocker and angiotensin-converting enzyme inhibitor use and survival in gastric cancer patients: a Finnish nationwide cohort study	17
A systematic review on the effectiveness of robot-assisted minimally invasive gastrectomy	17
Impact of adjuvant therapy on outcomes of cancer of the stomach and gastroesophageal junction in the real-world	17
Numerous lesions of gastric adenocarcinoma of fundic-gland and fundic gland-mucosa type in a patient	17
Multi-omics sequencing of gastroesophageal junction adenocarcinoma reveals prognosis-relevant key factors and a novel immunogenomic classification	16
Correction to: Effectiveness of second-look endoscopy after gastric endoscopic submucosal dissection in patients taking antithrombotic agents: a multicenter propensity score matching analysis	16
Lipolysis-stimulated lipoprotein receptor promote lipid uptake and fatty acid oxidation in gastric cancer	16
Factors associated with the efficacy of first-line nivolumab plus chemotherapy in advanced gastric cancer patients with deficient mismatch repair	16
The RNA-binding protein YTHDF3 affects gastric cancer cell migration and response to paclitaxel by regulating EZRIN	16
International Delphi consensus guidelines for follow-up after prophylactic total gastrectomy: the Life after Prophylactic Total Gastrectomy (LAP-TG) study	16
Impact of histologically poorly cohesive phenotype as a prognostic factor in patients with pStage II/III gastric cancer undergoing adjuvant chemotherapy	16
Investigating the role of inflammatory cytokines in mediating the effect of gut microbiota on gastrointestinal cancers: a mendelian randomization study	16
SUSD2+ cancer-associated fibroblasts in gastric cancer mediate the effect of immunosuppression and predict overall survival and the effectiveness of neoadjuvant immunotherapy	16
Clinical outcomes of Epstein–Barr virus (EBV)-associated metastatic and locally advanced unresectable gastric cancers (GCs) in patients receiving first-line fluoropyrimidine and platinum (FP) doublet	16
Asian consensus on normothermic intraperitoneal and systemic treatment for gastric cancer with peritoneal metastasis	15
TMEM205 induces TAM/M2 polarization to promote cisplatin resistance in gastric cancer	15
Appetite-preserving gastrectomy (APG) for esophagogastric junction cancer: preserving the residual stomach as an endocrine organ	15
Leptomeningeal carcinomatosis in gastric cancer: A Review	15
Impact of perioperative fluorouracil, leucovorin, oxaliplatin, and docetaxel delivery on postoperative survival in locally advanced oesophagogastric adenocarcinoma	15
Thromboembolic events in patients who received adjuvant chemotherapy for gastric cancer: a single-center retrospective study	15
Removal of small extracellular vesicles inhibits the progression of peritoneal dissemination in gastric cancer	15
Low positivity rate of fibroblast growth factor receptor 2b is associated with heterogeneous expression in gastric cancer	14
Response to neoadjuvant chemotherapy and survival in molecular subtypes of resectable gastric cancer: a post hoc analysis of the D1/D2 and CRITICS trials	14
Predictive value of homologous recombination-related gene mutations in survival outcomes of first-line nivolumab plus chemotherapy for gastric cancer	14
Ethnic-specific associations between body mass index and gastric cancer: a Mendelian randomization study in European and Korean populations	14
ATF4-mediated circTDRD3 promotes gastric cancer cell proliferation and metastasis by regulating the miR-891b/ITGA2 axis and AKT signaling pathway	14
Health-related quality-of-life outcomes with regorafenib in advanced gastric and esophagogastric junction cancer: results from the INTEGRATE trials	14

A retrospective 5-year survival analysis of surgically resected gastric cancer cases from the Japanese Gastric Cancer Association nationwide registry (2001–2013)	14
Efficacy and safety of trifluridine/tipiracil in older and younger patients with metastatic gastric or gastroesophageal junction cancer: subgroup analysis of a randomized phase 3 study (TAGS)	14
Morbidity and quality of life of totally laparoscopic versus laparoscopy-assisted distal gastrectomy for early gastric cancer: a multi-center prospective randomized controlled trial (CKLASS01)	13
Reply to the letter to the editor regarding “Appetite-preserving gastrectomy (APG) for esophagogastric junction cancer: preserving the residual stomach as an endocrine organ”	13
Comparison of clinicopathological features of gastric carcinoma in autoimmune gastritis with and without Helicobacter pylori infection	12
Letter to the editor: 5-year follow-up results of a JCOG1104 (OPAS-1) phase III non-inferiority trial to compare 4 courses and 8 courses of S-1 adjuvant chemotherapy for pathological stage II gastric	12
Reply to: Letter to editor on the article “Choice of PD-L1 immunohistochemistry assay influences clinical eligibility for gastric cancer immunotherapy”	12
Tumor-infiltrating monocytic myeloid-derived suppressor cells contribute to the development of an immunosuppressive tumor microenvironment in gastric cancer	12
N6-methyladenosine-modified MIB1 promotes stemness properties and peritoneal metastasis of gastric cancer cells by ubiquitinating DDX3X	12
Minimum resection length to ensure a pathologically negative distal margin and a larger remnant stomach for esophagogastric junction cancer	12
The clinical importance of the host anti-tumour reaction patterns in regional tumour draining lymph nodes in patients with locally advanced resectable gastric cancer: a systematic review and meta-anal	12
Circulating tumor DNA predicts recurrence and survival in patients with resectable gastric and gastroesophageal junction cancer	12
Clinical relevance of PD-1 positive CD8 T-cells in gastric cancer	11
Safety and feasibility of single-incision laparoscopic distal gastrectomy in overweight and obese gastric cancer patients: a propensity score-matched analysis	11
Biological and targeting differences between the rare KRAS A146T and canonical KRAS mutants in gastric cancer models	11
Clinical epidemiology of the endoscopic, laparoscopic, and surgical resection of malignant gastric tumors in Japan, 2014–2021: a retrospective study using open data from a national claims database	11
Limitations of the cox proportional hazards model and alternative approaches in metachronous recurrence research	11
Comment on:“Gastric equivalent of the ‘Holy Plane’ to standardize the surgical concept of stomach cancer to mesogastric excision: updating Jamieson and Dobson’s historic schema,” Gastric cancer, 2021	11
Effectiveness of second-look endoscopy after gastric endoscopic submucosal dissection in patients taking antithrombotic agents: a multicenter propensity score matching analysis	10
Early endpoints of a randomized phase II trial of preoperative chemotherapy with S-1/CDDP with or without trastuzumab followed by surgery for HER2-positive resectable gastric or esophagogastric juncti	10
Minimum resection length to ensure a pathologically negative distal margin and the preservation of a larger remnant stomach in proximal gastrectomy for early upper gastric cancer	10
SOX combined with sintilimab versus SOX alone in the perioperative management of locally advanced gastric cancer: a propensity score–matched analysis	10
Development of adenovirus-based oncolytic virus to induce EBV lytic reactivation	10
Elucidating molecular mechanisms and therapeutic synergy: irreversible HER2-TKI plus T-Dxd for enhanced anti-HER2 treatment of gastric cancer	10
Circulating tumor DNA predicts outcome in metastatic gastroesophageal cancer	10
CDKN2A somatic copy number amplification in normal tissues surrounding gastric carcinoma reduces cancer metastasis risk in droplet digital PCR analysis	10
Neoadjuvant chemotherapy in relation to long-term mortality in individuals cured of gastric adenocarcinoma	9
5-year follow-up results of a JCOG1104 (OPAS-1) phase III non-inferiority trial to compare 4 courses and 8 courses of S-1 adjuvant chemotherapy for pathological stage II gastric cancer	9
LRG1 mediated by ATF3 promotes growth and angiogenesis of gastric cancer by regulating the SRC/STAT3/VEGFA pathway	9
Impact of body composition on survival of PD-1/PD-L1-treated metastatic gastro-esophageal junction/gastric cancer	9
Failure of evaluation on ABC classification for gastric cancer screening	9
Interruption of imatinib in advanced gastrointestinal stromal tumor after prolonged imatinib maintenance in the absence of gross tumor lesions	9
Importance of duodenal stump reinforcement to prevent stump leakage after gastrectomy: a large-scale multicenter retrospective study (KSCC DELICATE study)	9
A multi-institutional study to evaluate the feasibility of next-generation sequencing and genomic analysis using formalin-fixed, paraffin-embedded biopsies of gastric cancer	9
Gallbladder edema as a clue to zolbetuximab-associated protein-losing enteropathy in gastric cancer: a case report	9
SPRY4 inhibits and sensitizes the primary KIT mutants in gastrointestinal stromal tumors (GISTs) to imatinib	9
Cardiovascular and thromboembolic outcomes with immune checkpoint inhibitors in gastroesophageal cancer: a propensity score-matched cohort study	9
IL-17A promotes Helicobacter pylori-induced gastric carcinogenesis via interactions with IL-17RC	8
Nishi memorial award in gastric cancer	8
Negative impact of intraoperative blood loss on long-term outcome after curative gastrectomy for advanced gastric cancer: exploratory analysis of the JCOG1001 phase III trial	8
Racial disparities of gastric cancer in the USA: an overview of epidemiology, global screening guidelines, and targeted screening in a heterogeneous population	8
Neoadjuvant docetaxel, oxaliplatin and S‑1 (DOS) combination chemotherapy for patients with resectable adenocarcinoma of esophagogastric junction	8
Acknowledgment to Reviewers	8
Oncological similarities between large type 3 and type 4 tumors in patients with resectable gastric cancer: a propensity score-matched analysis of a multi-institutional dataset	8
Clinical impact of primary and secondary KIT mutations on the efficacy of molecular-targeted therapies in gastrointestinal stromal tumors	8
Japanese Gastric Cancer Treatment Guidelines 2021 (6th edition)	8
Recurrence of gastric cancer caused by implantation of tumor cells after percutaneous transesophageal gastrostomy	8
IL-1β derived from mixed-polarized macrophages activates fibroblasts and synergistically forms a cancer-promoting microenvironment	8
Concordance of microsatellite instability and mismatch repair status in paired biopsies and surgical specimens of resectable gastroesophageal adenocarcinoma: time for a call to action	8
Q-TWiST analysis of first-line nivolumab plus chemotherapy versus chemotherapy in patients with advanced gastric cancer, gastroesophageal junction cancer, or esophageal adenocarcinoma from CheckMate 6	8
Impact of early economic activity loss on all-cause mortality in gastric cancer survivors following curative treatment: a nationwide study in Korea	8
Identification of CD66c as a potential target in gastroesophageal junction cancer for antibody–drug conjugate development	7
The relationship between the gastric cancer microbiome and clinicopathological factors: a metagenomic investigation from the 100,000 genomes project and The Cancer Genome Atlas	7
Comment on “Comparative effectiveness of sodium-glucose cotransporter-2 inhibitors for new-onset gastric cancer and gastric diseases in patients with type 2 diabetes mellitus: a population-based cohor	7
Long-term adjuvant therapy for high-risk gastrointestinal stromal tumors in the real world	7
Neoadjuvant camrelizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastroesophageal junction adenocarcinoma: a single-arm, phase 2 trial	7
Combined loss of CDH1 and downstream regulatory sequences drive early-onset diffuse gastric cancer and increase penetrance of hereditary diffuse gastric cancer	7
LOC101929709 promotes gastric cancer progression by aiding LIN28B to stabilize c-MYC mRNA	7
Soluble factors in malignant ascites promote the metastatic adhesion of gastric adenocarcinoma cells	7
Chromosomal copy number amplification-driven Linc01711 contributes to gastric cancer progression through histone modification-mediated reprogramming of cholesterol metabolism	7
A comparative study of demarcation line diagnostic performance between non-magnifying observation with white light and non-magnifying observation with narrow-band light for early gastric cancer	7
Risk factors for gastric cancer in Japan in the 2010s: a large, long-term observational study	7
Heterogeneity of predictive biomarker expression in gastric and esophago-gastric junction carcinoma with peritoneal dissemination	7
Comparison of perioperative outcomes between bipolar sealing, ultrasonic shears and a hybrid device during laparoscopic gastrectomy for early gastric cancer: a prospective, multicenter, randomized stu	7
Functional genomics reveals an off-target dependency of drug synergy in gastric cancer therapy	7
COPS5 inhibition synergizes with the antitumor effect of trastuzumab by PTEN upregulation in HER2-amplified gastric cancer	7
Prevalence and clinicopathological features of microsatellite instability-high metastatic or recurrent gastric and esophagogastric junction cancer: WJOG13320GPS	7
Metachronous primary gastric cancer after endoscopic resection in patients with esophageal squamous cell carcinoma	7
Development and validation of a machine learning model for predicting immune checkpoint inhibitor efficacy in advanced gastric cancer using dynamic changes in peripheral blood clinlabomics data: a ret	6
Leukaemia inhibitory factor in gastric cancer: friend or foe?	6
National guidelines for gastric cancer: redundant or needed?	6
Burden of gastric cancer attributable to Helicobacter pylori in 27 countries from seven geographic regions in 2022	6
Circulating hormones and risk of gastric cancer by subsite in three cohort studies	6
Correction: Real-world effectiveness and safety of trastuzumab-deruxtecan in Japanese patients with HER2-positive advanced gastric cancer (EN-DEAVOR study)	6
Clinical impact of gastrectomy in surgically proven stage IV gastric cancers: retrospective analysis from Korean multicenter dataset (PASS-META)	6
Nishi memorial award in gastric cancer	6
Molecular profile of poorly cohesive gastric carcinoma with special reference to survival	6
A phase Ib study of photoimmunotherapy with ASP-1929 in combination with nivolumab for advanced gastric cancer (GE-PIT, EPOC1901)	6
Preferred neoadjuvant therapy for gastric and gastroesophageal junction adenocarcinoma: a systematic review and network meta-analysis	6
Risk factors of perforation in gastric stromal tumors during endoscopic resection: a retrospective case–control study	6

Tumorigenic mechanisms of estrogen and Helicobacter pylori cytotoxin-associated gene A in estrogen receptor α-positive diffuse-type gastric adenocarcinoma	6
Oncological impact of unexpected horizontal tumor spread in gastric cancer that requires total gastrectomy	6
Textbook outcome in gastrectomy: useful metric or moving target? A scoping review	6
Global burden of young-onset gastric cancer: a systematic trend analysis of the global burden of disease study 2019	6
Gastric tubular adenocarcinoma with diffuse neutrophils infiltrating: characteristics and probable treatment strategy	6
Early stage gastric cancer with unusual sarcomatous component and no recurrence after endoscopic submucosal dissection: a case report	5
Evaluating the efficacy of post-operative chemotherapy after curative resection of stage IV gastric cancer with synchronous oligo metastasis: a multicenter retrospective study	5
Adjuvant treatment for locally advanced gastric cancer: an Asian perspective	5
Short-term outcomes of preoperative chemotherapy with docetaxel, oxaliplatin, and S-1 for gastric cancer with extensive lymph node metastasis (JCOG1704)	5
Ubiquitination of ADRα1d/SerpinA1 complex stimulates hypoxia to induce gastric tumorigenesis with a combination of Helicobacter pylori and chronic stress through IL-1α	5
Inhibition of proprotein convertases activity results in repressed stemness and invasiveness of cancer stem cells in gastric cancer	5
Correction: Ubiquitous mitochondrial creatine kinase promotes the progression of gastric cancer through a JNK-MAPK/JUN/HK2 axis regulated glycolysis	5
Clinical practice guidelines for esophagogastric junction cancer: Upper GI Oncology Summit 2023	5
Deep learning for automatic diagnosis of gastric dysplasia using whole-slide histopathology images in endoscopic specimens	5
Clinicopathological and genomic features of extrachromosomal DNA in gastric cancer	5
Superior lymph node harvest by fluorescent lymphography during minimally invasive gastrectomy for gastric cancer patients with high body mass index	5
Helicobacter pylori-naïve status is associated with poor prognosis and aggressive pathological features in undifferentiated-type gastric cancer: a multi-center retrospective cohort study	5
The molecular profile of gastric intraepithelial foveolar type neoplasia based on somatic copy number alterations and multiple mutation analysis	5
Feasibility of intraoperative pathologic examination for sentinel lymph nodes during sentinel node navigation surgery in early gastric cancer: results of pathologic protocol for SENORITA trial	5
Development of the PERI-Gastric (PEritoneal Recurrence Index) and PERI-Gram (Peritoneal Recurrence Index NomoGRAM) for predicting the risk of metachronous peritoneal carcinomatosis after gastrectomy w	5
Long-term outcomes of a phase II study of neoadjuvant imatinib in large gastrointestinal stromal tumors of the stomach	5
Effects of RAD50 SNP, sodium intake, and H. pylori infection on gastric cancer survival in Korea	4
CEACAM5 and TROP2 define metaplastic and dysplastic transitions in human antral gastric precancerous lesions and tumors	4
YAP as a therapeutic target to reverse trastuzumab resistance	4
The Magic Flute is a Singspiel, not an opera? My thoughts about the German, Austrian and Swiss Guidelines for Systemic Treatment of Gastric Cancer	4
Relationship between antithrombotic drugs and postoperative outcomes in patients with gastric cancer after gastrectomy: a propensity matching analysis	4
A nonrandomized controlled trial: long-term outcomes of LATG/LAPG for cStage I gastric cancer: Japan Clinical Oncology Group Study JCOG1401	4
Multicenter phase II study on the efficacy of an oral nutritional supplement containing eicosapentaenoic acid in advanced gastric cancer patients with cachexia	4
An artificial intelligence system for comprehensive pathologic outcome prediction in early gastric cancer through endoscopic image analysis (with video)	4
Second-line chemoimmunotherapy with nivolumab and paclitaxel in immune-related biomarker-enriched advanced gastric cancer: a multicenter phase Ib/II study	4
Transcriptome analysis reveals the essential role of NK2 homeobox 1/thyroid transcription factor 1 (NKX2-1/TTF-1) in gastric adenocarcinoma of fundic-gland type	4
Correction to: DNA methylation downregulated mir-10b acts as a tumor suppressor in gastric cancer	4
Correction: An artificial intelligence system for comprehensive pathologic outcome prediction in early gastric cancer through endoscopic image analysis (with video)	4
Dihydrotestosterone-androgen receptor signaling suppresses EBV-positive gastric cancer through DNA demethylation-mediated viral reactivation	4
Deep learning predicts resistance to neoadjuvant chemotherapy for locally advanced gastric cancer: a multicenter study	4
Classification based on tumor phenotypes enables the novel molecular characterization of esophagogastric junction cancer	4
Long-term oncological outcomes of 3D versus 2D laparoscopic gastrectomy for gastric cancer: a randomized clinical trial	4
The occurrence, progression and development of four types of gastric mucosal atrophic lesions and their histopathological characteristics	4
Cancer-associated fibroblasts-derived HAPLN1 promotes tumour invasion through extracellular matrix remodeling in gastric cancer	4
Body weight loss as a prognostic and predictive factor in previously treated patients with metastatic gastric cancer: post hoc analyses of the randomized phase III TAGS trial	4
Lipocalin-2 negatively regulates epithelial–mesenchymal transition through matrix metalloprotease-2 downregulation in gastric cancer	4
Interdisciplinary insights into the link between gut microbiome and gastric carcinogenesis—what is currently known?	4
PD-L1 IHC testing: issues with interchangeability evidence based on laboratory-developed assays of unknown analytical performance	4
Impact of preoperative prealbumin levels on long-term prognosis in patients with gastric cancer after gastrectomy: a retrospective cohort study	4
Correction: Spatial organization of B lymphocytes and prognosis prediction in patients with gastric cancer	4
Development of the PERI-Gastric (PEritoneal Recurrence Index) and PERI-Gram (Peritoneal Recurrence Index NomoGRAM) for predicting the risk of metachronous peritoneal carcinomatosis after gastrectomy w	4
Discordant PD-L1 results between 28–8 and 22C3 assays are associated with outcomes of gastric cancer patients treated with nivolumab plus chemotherapy	3
Correction: A nonrandomized, single-arm confirmatory trial of expanded endoscopic submucosal dissection indication for undifferentiated early gastric cancer: Japan Clinical Oncology Group study (JCOG1	3
Bemarituzumab as first-line treatment for locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma: final analysis of the randomized phase 2 FIGHT trial	3
Improved survival after laparoscopic compared to open gastrectomy for advanced gastric cancer: a Swedish population-based cohort study	3
Incidence and risk factors of tuberculosis in patients following gastrectomy or endoscopic submucosal dissection: a cohort analysis of country-level data	3
Eligibility criteria in phase 3 randomized controlled trials in gastric cancer	3
Usefulness of an S-1 dosage formula: an exploratory analysis of randomized clinical trial (JCOG1001)	3
Efficacy and safety of trifluridine/tipiracil plus ramucirumab in comparison with trifluridine/tipiracil monotherapy for patients with advanced gastric cancer–single institutional experience	3
Collagen-related gene expression level predicts the prognosis and immune therapy response	3
Down-regulation of stimulator of interferon genes (STING) expression and CD8+ T-cell infiltration depending on HER2 heterogeneity in HER2-positive gastric cancer	3
Risk assessment of metachronous gastric cancer development using OLGA and OLGIM systems after endoscopic submucosal dissection for early gastric cancer: a long-term follow-up study	3
Oncological outcomes of conversion therapy in gastric cancer patients with peritoneal metastasis: a large-scale retrospective cohort study	3
Heterogeneity and evolution of tumour immune microenvironment in metastatic gastroesophageal adenocarcinoma	3
Molecular features and prognostic factors of locally advanced microsatellite instability-high gastric cancer	3
Clinicopathological significance of JAK2, STAT3, and STAT4 expression in patients with gastric solid-type poorly differentiated adenocarcinoma: a retrospective study	3
Direct prediction of genetic aberrations from pathology images in gastric cancer with swarm learning	3
Evaluation of the widths of the mucosal strips in pathological examination of specimens of endoscopic submucosal dissection for early gastric cancer	3
Photodynamic therapy improves the outcome of immune checkpoint inhibitors via remodelling anti-tumour immunity in patients with gastric cancer	3
The oncogenic role of hypomethylated ZNF793 in gastric carcinoma: a focus on cell survival and stemness	3
Reply to letter to the editor: “5-year follow-up results of a JCOG1104 (OPAS-1) phase III noninferiority trial to compare 4 courses and 8 courses of S-1 adjuvant chemotherapy for pathological stage II	3
Incidence and risk factors for venous thromboembolism in the Cancer-VTE Registry stomach cancer subcohort	3
Correction to: DLX6-AS1/miR-204-5p/OCT1 positive feedback loop promotes tumor progression and epithelial–mesenchymal transition in gastric cancer	3
Effect of the number of cycles of docetaxel + S-1 therapy on long-term survival in adjuvant chemotherapy for stage III gastric cancer. A pooled analysis of the OGSG0604 and OGSG1002 trials	3
PPARδ dysregulation of CCL20/CCR6 axis promotes gastric adenocarcinoma carcinogenesis by remodeling gastric tumor microenvironment	3
Preclinical toxicological assessment of amido-bridged nucleic acid-modified antisense oligonucleotides targeting synaptotagmin XIII for intra-abdominal treatment of peritoneal metastasis of gastric ca	3
Anthracycline chemicals with anthracyclinone structure exert antitumor effects by inhibiting angiogenesis and lymphangiogenesis in a xenografted gastric tumor model	3
Lysosomal-associated membrane protein family member 5 promotes the metastatic potential of gastric cancer cells	3
SMARCA4-deficient undifferentiated gastric carcinoma: a case series and literature review	3
Transformer-based skeletal muscle deep-learning model for survival prediction in gastric cancer patients after curative resection	3